Forbion related stories
All articles and analysis
Enterprise Therapeutics raises 29 mln poundsEnterprise Therapeutics Ltd said April 12 that it raised 29 million pounds ($41 million) in a Series B round co-led by Versant Ventures and Novartis Venture Fund. The syndicate also included new investor Forbion, founding investor Epidarex Capital and existing investor IP Group. Enterprise Therapeutics Ltd is a biopharmaceutical company that is developing therapies for the treatment of respiratory diseases.
- Lundbeck to acquire VC-backed Prexton
Lundbeck has agreed to acquire Prexton Therapeutics for 100 million euros and will later pay up to 805 million euros in development and sales milestones. Based in The Netherlands and in Switzerland, Prexton is a biopharmaceutical company. Prexton's investors include Forbion, Seroba Life Sciences, Sunstone Capital and Ysios Capital.
- Dutch biotech company NorthSea Therapeutics collects Series A funding
NorthSea Therapeutics B.V., a Dutch biotech company, has closed 25 million euros in Series A funding. Forbion and BGV led the round with participation from Novo Seeds and New Science Ventures.
- BioGeneration Ventures Fund III raises $95.3 mln
BioGeneration Ventures said Oct. 31 that it closed its third fund with 82 million euros ($95.3 million) in funding, exceeding its 50 million euro ($58.1 million) target. New investors include Bristol-Myers Squibb, Johnson & Johnson Innovation – JJDC Inc, as well as Schroder Adveq, and the MAN Pension Trust. BGV III will focus on seed investments in European biotechnology companies.
- Replimune pulls in $55 mln Series B
UK-based Replimune, a developer of oncolytic immunotherapy, has closed $55 million in Series B financing. Foresite Capital led the round with participation from other investors that included Bain Capital Life Sciences, Redmile Group, Cormorant Asset Management, Leerink Partners, Atlas Venture, Forbion Capital Partners and Omega Funds. In addition to the funding, Dr. Brett Zbar of Foresite Capital and Dr. Kapil Dhingr, the former head of clinical oncology at Roche, will join Replimune's board of directors.
Milestone Pharmaceuticals nets $68 mln in Novo-led Series CMontréal clinical-stage cardiovascular company Milestone Pharmaceuticals Inc has secured more than $68 million (US$55 million) in a Series C financing. The round, which brings Milestone's total funding to more than $100 million, was led by Denmark's Novo Holdings A/S. It was joined by new and existing investors, including Forbion Capital Partners, Tekla Capital Management, Domain Associates, Fonds de solidarité FTQ, BDC Capital, Pappas Capital and GO Capital. The funds raised will be used to advance Milestone's lead product, etripamil, into Phase 3 and pre-launch development. Founded in 2005, Milestone is led by President and CEO Joseph Oliveto.
- VarmX closes seed round
VarmX said June 27 that it closed a seed financing round. New investors include BioGeneration Ventures (BGV) and InnovationQuarter. VarmX, of Leiden, Netherlands, is a biotech company focusing on the development of therapies in the field of hemostasis and thrombosis.
- Prexton Therapeutics raises $31 mln
Prexton Therapeutics said Feb. 7 that it has closed a 29 million euro ($31 million) Series B round led by Forbion Capital Partners and Seroba Life Sciences. Also participating were Merck Ventures (NL), Ysios Capital (ES) and Sunstone Capital (DK). Prexton, of Naarden, the Netherlands, is a biopharmaceutical company developing therapeutic compounds for the treatment of central nervous system conditions.
- Allergan buys VC-backed Akarna
Allergan plc has acquired Akarna for $50 million. Moelis & Company LLC served as financial adviser to Akarna. Based in San Diego and the UK, Akarna is a biopharmaceutical company focused on inflammatory and fibrotic diseases for which there is no approved treatment. Akarna's backers included Forbion Capital Partners, New Science Ventures LLC and Third Point Ventures.
- Allecra Therapeutics raises $24.7 mln
Allecra Therapeutics said June 15 that it raised 22 million euros ($24.7 million) in a Series B round led by Delos Capital. Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures and Allecra's co-Founder Nicholas Benedict also participated. Allecra is a biopharmaceutical company that is developing antibiotics to combat drug-resistant bacterial infections.